Weiwei Sui

1.3k total citations
82 papers, 575 citations indexed

About

Weiwei Sui is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Weiwei Sui has authored 82 papers receiving a total of 575 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Hematology, 39 papers in Oncology and 33 papers in Molecular Biology. Recurrent topics in Weiwei Sui's work include Multiple Myeloma Research and Treatments (50 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (18 papers). Weiwei Sui is often cited by papers focused on Multiple Myeloma Research and Treatments (50 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (18 papers). Weiwei Sui collaborates with scholars based in China, United States and United Kingdom. Weiwei Sui's co-authors include Lugui Qiu, Dehui Zou, Shuhui Deng, Yan Xu, Mu Hao, Gang An, Shuhua Yi, Zengjun Li, Fei Li and Yaozhong Zhao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Scientific Reports.

In The Last Decade

Weiwei Sui

68 papers receiving 573 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weiwei Sui China	12	373	355	232	121	113	82	575
Marina Martello Italy	10	352 0.9×	303 0.9×	218 0.9×	83 0.7×	48 0.4×	30	472
Daniele Derudas Italy	9	494 1.3×	369 1.0×	258 1.1×	47 0.4×	127 1.1×	30	624
Enrica Borsi Italy	12	239 0.6×	243 0.7×	157 0.7×	83 0.7×	34 0.3×	26	392
Normann Steiner Austria	14	180 0.5×	219 0.6×	191 0.8×	44 0.4×	98 0.9×	55	471
Sara Gandolfi United States	10	247 0.7×	328 0.9×	172 0.7×	41 0.3×	38 0.3×	28	491
Norbert Grząśko Poland	13	356 1.0×	285 0.8×	237 1.0×	54 0.4×	49 0.4×	39	488
Valeria Magarotto Italy	12	565 1.5×	669 1.9×	345 1.5×	33 0.3×	61 0.5×	32	837
Stéphanie Guidez France	10	170 0.5×	126 0.4×	155 0.7×	60 0.5×	134 1.2×	45	387
Kimihito C. Kawabata Japan	9	291 0.8×	323 0.9×	90 0.4×	81 0.7×	123 1.1×	18	529
Assunta Melaccio Italy	13	222 0.6×	242 0.7×	180 0.8×	94 0.8×	52 0.5×	29	473

Countries citing papers authored by Weiwei Sui

Since Specialization

Citations

This map shows the geographic impact of Weiwei Sui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Sui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Sui more than expected).

Fields of papers citing papers by Weiwei Sui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiwei Sui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Sui. The network helps show where Weiwei Sui may publish in the future.

Co-authorship network of co-authors of Weiwei Sui

This figure shows the co-authorship network connecting the top 25 collaborators of Weiwei Sui. A scholar is included among the top collaborators of Weiwei Sui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiwei Sui. Weiwei Sui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yi, Yuting Yan, Dandan Shan, et al.. (2025). Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma. Cancer Biology and Medicine. 22(2). 177–189. 1 indexed citations

Liu, Wei, Xiaojuan Wang, Chunyang Wang, et al.. (2024). Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Journal for ImmunoTherapy of Cancer. 12(3). e008450–e008450. 9 indexed citations

Xiong, Yu, Tengteng Yu, Shuaishuai Zhang, et al.. (2024). Uncommon biphasic CAR-T expansion induces hemophagocytic lymphohistiocytosis-like syndrome and fatal multiple infections following BCMA CAR-T cell therapy: a case report. Journal for ImmunoTherapy of Cancer. 12(11). e010080–e010080. 2 indexed citations

Sui, Weiwei, Tengteng Yu, Yuting Yan, et al.. (2024). CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities. Blood. 144(Supplement 1). 3386–3386.

Sui, Weiwei, et al.. (2024). BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review. Critical Reviews in Oncology/Hematology. 205. 104551–104551. 1 indexed citations

Liu, Jiahui, Yan Xu, Weiwei Sui, et al.. (2024). Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. American Journal of Hematology. 99(4). 523–533. 7 indexed citations

Xu, Yan, Wensi Li, Gang An, et al.. (2023). Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy. Blood. 142(Supplement 1). 6864–6864. 1 indexed citations

Shi, Lihui, Lingna Li, Jian Cui, et al.. (2023). Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM). Annals of Hematology. 103(4). 1305–1315. 1 indexed citations

Yu, Zhen, Xiaojing Wei, Lanting Liu, et al.. (2022). Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine. 78. 103950–103950. 27 indexed citations

10.

Sun, Hao, Tingyu Wang, Zhen Yu, et al.. (2022). Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia. Journal of Translational Medicine. 20(1). 576–576. 10 indexed citations

11.

Yu, Tengteng, Xiaoke Ma, Weiwei Sui, et al.. (2020). Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Molecular Cancer Research. 18(7). 1063–1073. 21 indexed citations

12.

Liu, Lanting, Zhen Yu, Hui Cheng, et al.. (2020). Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Scientific Reports. 10(1). 20508–20508. 33 indexed citations

13.

Deng, Shuhui, Yan Xu, Gang An, et al.. (2015). [Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China].. PubMed. 36(6). 501–6. 1 indexed citations

14.

Hao, Mu, Meirong Zang, Yan Xu, et al.. (2015). Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis. Blood. 126(23). 4186–4186. 2 indexed citations

15.

Feng, Xiaoyan, Shuhui Deng, Gang An, et al.. (2015). [Clinical characteristics and survival of newly diagnosed multiple myeloma patients under 40 years old from single center and literature review].. PubMed. 36(11). 933–6. 1 indexed citations

16.

Li, Fei, Mu Hao, Xiaoyan Feng, et al.. (2015). Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma. Leukemia Research. 39(7). 793–799. 22 indexed citations

17.

Zou, Dehui, Changhong Li, Hengxing Meng, et al.. (2015). Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment. Stem Cell Research & Therapy. 6(1). 175–175. 23 indexed citations

18.

Deng, Shuhui, Yan Xu, Gang An, et al.. (2015). Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases. Clinical Lymphoma Myeloma & Leukemia. 15(5). 286–291. 52 indexed citations

19.

Sui, Weiwei, Haibing Ding, Gui‐Peng Yang, et al.. (2013). [Simulated study of algal fatty acid degradation in hypoxia seawater-sediment interface along China coastal area].. PubMed. 34(11). 4231–9. 1 indexed citations

20.

An, Gang, Yan Xu, Lihui Shi, et al.. (2013). t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leukemia Research. 37(10). 1251–1257. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact